Uveal Melanoma With Liver Metastases
2
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Tislelizumab
Research Leaders
5 sponsors active, led by Grupo Español Multidisciplinar de Melanoma
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 2 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
Research Network
Common Treatments
- Tislelizumab1
- Melphalan1
- Interleukin21
- Autologous Tumor Infiltrating Lymphocytes1
Active Sponsors
- Grupo Español Multidisciplinar de Melanoma1
- BeiGene1
- Mirati Therapeutics Inc.1
- Vastra Gotaland Region1
- Miltenyi Biomedicine GmbH1
Top Investigators
Department of Oncology, Sahlgrenska University Hospital, Sweden
ICO L´Hospitalet
Related Conditions
- Metastatic Cutaneous Melanoma1
- Metastatic Uveal Melanoma1
- Ocular Melanomas1
- Skin Melanomas1
- Metastases To Liver1